Related Experiment Video
Updated: Jun 29, 2026
08:34
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Permanent implant prostate cancer brachytherapy]
J-M Cosset1, T Flam, N Thiounn
1Département d'oncologie et radiothérapie, institut Curie, 26, rue d'Ulm, 75005 Paris, France. jean-marc.cosset@curie.net
Summary
Permanent implant brachytherapy with Iodine-125 seeds offers excellent long-term results for prostate cancer. This radiation therapy shows high survival rates and fewer side effects compared to surgery.
Area of Science:
- Oncology
- Radiation Therapy
- Urology
Context:
- Permanent implant brachytherapy using Iodine-125 seeds has over 20 years of pioneering experience.
- It is a recognized treatment for localized low-risk prostate cancer.
- Current research explores its use in intermediate-risk and as an adjunct for high-risk prostate cancer.
Purpose:
- To evaluate the efficacy and outcomes of permanent implant brachytherapy for prostate cancer.
- To discuss various techniques and the importance of dosimetric compliance.
- To compare brachytherapy outcomes with other treatment modalities like surgery.
Summary:
- Relapse-free survival rates of approximately 90% at 5-10 years are reported with satisfactory dosimetry.
- Brachytherapy demonstrates significantly lower rates of incontinence and impotence compared to surgery.
- Potential drawbacks include a 3-5% risk of urinary retention and temporary irritative urinary symptoms.
Impact:
- Permanent brachytherapy is a valuable, minimally invasive treatment option for prostate cancer.
- It offers excellent long-term survival with favorable functional outcomes.
- Its indications are expanding, suggesting increased future use in patient care.
